Overview

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Phase:

Phase 2

Details

Lead Sponsor:

Imbria Pharmaceuticals, Inc.